(DumbMoney.)

Explore the latest updates and key analyses on companies, markets, and industry trends.


Leveraging Genetics to Treat Neurological Diseases - Citi 2025 Biopharma Back to School Conference

Voyager Therapeutics, Inc. (VYGR) | September 2, 2025

By Quinn Adams

image

Voyager Therapeutics focuses on leveraging genetics to treat neurological diseases.

The presentation contains forward-looking statements regarding Voyager's development milestones and partnerships.

This filing showcases Voyager's commitment to advancing neurogenetic medicine.

Development Milestones

Voyager aims to achieve preclinical and clinical development milestones for potential candidates.

Partnership Funding

Seeking near-term and long-term funding through collaboration agreements and royalty-based fees.

Technology Platforms

Voyager emphasizes TRACER capsid discovery and non-viral platforms in its scientific approach.

  • Voyager's focus on neurogenetic medicine presents significant potential for breakthrough therapies.
  • The company's strategic partnerships are crucial for advancing its pipeline and securing funding.

Voyager Therapeutics, Inc. stands at the forefront of genetic therapies for neurological conditions, demonstrating a commitment to innovation and collaboration in the biopharma industry.